search
for
 About Bioline  All Journals  Testimonials  Membership  News


Indian Journal of Pharmacology
Medknow Publications on behalf of Indian Pharmacological Society
ISSN: 0253-7613 EISSN: 1998-3751
Vol. 41, Num. 2, 2009, pp. 89-90

Indian Journal of Pharmacology, Vol. 41, No. 2, March-April, 2009, pp. 89-90

Case Report

Baclofen intoxication after accidental ingestion in a 3-year-old child

Pediatric Intensive Care Unit, Department of Pediatrics, Lokmanya Tilak Municipal Medical College and General Hospital, Sion, Mumbai - 400 022
Correspondence Address:Pediatric Intensive Care Unit, Department of Pediatrics, Lokmanya Tilak Municipal Medical College and General Hospital, Sion, Mumbai - 400 022
pshanbag@gmail.com

Date of Submission: 15-Aug-2008
Date of Decision: 16-Jan-2009
Date of Acceptance: 30-Mar-2009

Code Number: ph09025

DOI: 10.4103/0253-7613.51349

Abstract

Baclofen is a skeletal muscle relaxant, used to control spasticity in both adults and children with neuromuscular disorders. Several cases of baclofen overdose have been reported, but only a small number have involved children. We report a 3-year-old girl with accidental ingestion of baclofen, who presented with coma, bradycardia and hypotension. She recovered within 24 hours with supportive treatment. The case emphasizes the importance of warning parents about the potential toxicity of baclofen when the drug is prescribed to a family member.

Keywords: Accidental ingestion, baclofen, toxicity

Introduction

Baclofen is an analog of the naturally-occurring inhibitory neurotransmitter gamma-aminobutyric acid (GABA) found in the central nervous system. Specifically, baclofen binds to GABA b receptors, inhibiting the influx of calcium and thus preventing the release of the excitatory neurotransmitters glutamate and aspartate. [1]

The drug is administered orally to treat spasticity associated with spinal lesions such as traumatic injuries and demyelination as in multiple sclerosis. It is used intrathecally in treating spasticity associated with supraspinal lesions like cerebral palsy and stroke. [1] Baclofen has also been used for treating chronic hiccups and for cocaine abuse. [2],[3] Lately, it has also become popular as a recreational drug. [4] Baclofen overdose can result in coma, seizures, respiratory depression, cardiac rhythm abnormalities and rhabdomyolysis. [4],[5]

We describe a case of baclofen toxicity presenting with coma, flaccidity, hyporeflexia, bradycardia and hypotension.

Case Report

A previously well 3-year-old girl presented to us with sudden onset of unresponsiveness. She was brought to the hospital within half an hour of onset of symptoms. There was no history of fever, convulsions or head injury. Despite inquiry no history of drug ingestion could be elicited. The child′s development was appropriate for her age. Physical examination revealed a deeply comatose child with a Glasgow Coma Scale (GCS) score of 3. She was normothermic with a heart rate of 70/minute, respiratory rate of 24/minute and blood pressure of 62/40mmHg. There was no icterus or pallor, nor were there any signs of injury. There was no peculiar odor to the breath or the clothes. The weight was 13kg (25 th percentile for age). The pupils were neither pinpoint nor were they dilated, and were reacting well to light. Extra-ocular movements were normal. Generalized hypotonia was present and the deep tendon reflexes could not be elicited. There was no focal neurological deficit, nor signs of meningeal irritation. The fundus showed no papilledema or hemorrhages. On examination of the respiratory system, breath sounds were normally heard and there were no adventitious sounds. Examination of the abdomen revealed no hepato-splenomegaly.

In view of the low blood pressure, the child was given an intravenous bolus of 20ml/kg of normal saline and continued on intravenous fluids and dopamine. Intravenous ceftriaxone was started for suspected meningo-encephalitis and discontinued after 48 hours when the CSF culture was reported as sterile.

Blood sugar at admission was 108 mg/dL. Pulse oximetry revealed an oxygen saturation of 98%. The hemoglobin was 10.3g/dL. The total WBC count was 17,800/mm 3 with a differential of lymphocytes 64%, polymorphs 34% and monocytes 2% and the platelet count 3,47,000/mm 3 . C-reactive protein was 5.6mg/L (cut-off for bacterial infection in children 35-60mg/L). Lumbar puncture done after stabilization of the child showed 2 cells/mm 3 , both lymphocytes. Cerebrospinal spinal fluid (CSF) sugar was 64mg/dL and protein 42mg/dL. CSF culture was reported as sterile. A computed tomography (CT) scan of the brain was normal. The blood urea nitrogen was 3mg/dL, serum creatinine was 0.9mg/dL. The liver function tests showed a total protein of 6.9g/dL, albumin 4g/dL, globulin 2.9g/dL and total serum bilirubin 0.9mg/dL. Serum aspartate aminotransferase (AST) was 19 U/L, serum alanine aminotransferase (ALT) 33U/L and serum alkaline phosphatase 277U/L. The electrocardiogram showed sinus bradycardia.

Six hours after admission, additional history given by an older sibling revealed that the child had been playing with some tablets and had swallowed some. The father had been prescribed baclofen (Lioresal) for frequent hiccups and on checking found six 10mg tablets of baclofen missing. The exact time of ingestion of the tablets could not be ascertained. Gastric lavage was subsequently done. Since baclofen is excreted primarily via the kidney, the patient was started on vigorous hydration and forced alkaline diuresis. Five hours after starting this therapy, the child showed signs of improvement in the form of an increase in the heart rate to 92/minute, stable blood pressure and increase in the Glasgow Coma Scale to 10 (E3M4V3). Within 24 hours the child had regained normal consciousness, and heart rate and blood pressure were normal. The child was transferred to the general ward after 48 hours and subsequently discharged.

Discussion

Our patient presented with coma, hypotonia, hyporeflexia, bradycardia and hypotension.

Symptoms of baclofen toxicity generally appear within 2 to 6 hours of ingestion and include hypoventilation, coma, flaccidity, hyporeflexia and hypothermia. Autonomic disturbances are frequent but inconsistent; patients may have either bradycardia or tachycardia, hypotension or hypertension, and miosis or mydriasis. Seizures and conduction abnormalities are also seen. [6],[7] Seizures are generally brief, tonic-clonic, and respond rapidly to pharmacological intervention. Cardiac abnormalities observed include supraventricular tachycardia, premature atrial contractions, first degree heart block and prolonged QTc. [4],[7] Hallucinations may also occur, but are typically seen in patients who are chronically medicated with baclofen, who receive an acute overdose. [8] Rhabdomyolysis has also been described. [5] Laboratory abnormalities have included transient elevations of lactic dehydrogenase, AST, alkaline phosphatase and blood glucose. [4]

The management of baclofen toxicity is mainly supportive.[4] Gastric lavage and activated charcoal administration has been recommended for children who ingest more than 5mg/kg. The patient should be stabilized by maintaining the airway, breathing and circulation. Intubation and respiratory support may be needed if respiratory depression is present. No specific antidote to baclofen exists, however, if not contraindicated, physostigmine may be used to reduce central side effects such as somnolence and respiratory depression. [9] The treatment however, may not always be effective. [10] Atropine administered intravenously has also been shown to produce an increase in cardiac output, ventilation and temperature in a patient with baclofen overdose. [11] There is no role for extracorporeal removal. Hemodialysis is the modality of choice for baclofen intoxication in patients with impaired renal function. [12] Full supportive treatment results in good outcome, provided no hypoxic or ischemic insult has occurred before medical attention.

Acknowledgment

We would like to thank the Dr. ME Yeolekar, Dean of our institution for permitting us to publish this manuscript.

References

1.Ciccone CD, editor. Pharmacology In Rehabilitation . Philadelphia: FA Davis and Company; 2007.  Back to cited text no. 1    
2.Johnson BR, Kriel RL. Baclofen for chronic hiccups. Pediatr Neurol 1996;15:66-7.  Back to cited text no. 2  [PUBMED]  [FULLTEXT]
3.Vocci FJ, Elkashef A. Pharmacotherapy and other treatments for cocaine abuse and dependence. Curr Opin Psychiatry 2005;18:265-70.  Back to cited text no. 3  [PUBMED]  [FULLTEXT]
4.Perry HE, Wright RO, Shannon MW, Woolf AD. Baclofen overdose: Drug experimentation in a group of adolescents. Pediatrics 1998;101:1045-8.  Back to cited text no. 4  [PUBMED]  [FULLTEXT]
5.Chong CF, Wang TL. An unusual presentation of baclofen overdose. Emerg Med J 2005;22:673-4.  Back to cited text no. 5  [PUBMED]  [FULLTEXT]
6.Ghose K, Holmes KM, Matthewson K. Complications of baclofen overdosage. Postgrad Med J 1980;56:865-7.  Back to cited text no. 6  [PUBMED]  [FULLTEXT]
7.Nugent S, Katz MD, Little TE. Baclofen overdose with cardiac conduction abnormalities: Case report and review of the literature. Clin Toxicol 1986;24:321-8.  Back to cited text no. 7    
8.Lee TH, Chen SS, Su SL. Baclofen intoxication: Report of four cases and review of the literature. Clin Neuropharmacol 1992;15:56-62.  Back to cited text no. 8    
9.Muller-Schwefe G, Penn RD. Physostigmine in the treatment of intrathecal baclofen overdose: Report of 3 cases. J Neurosurg 1989;71:273-5.  Back to cited text no. 9    
10.Saltuari L, Baumgartner H, Kofler M, Schmutzhard E, Russegger L, Aichner F, et al . Failure of physostigmine in the treatment of acute severe intrathecal baclofen intoxication. N Engl J Med 1990;322:1533-4.  Back to cited text no. 10  [PUBMED]  
11.Ferner RE. Atropine treatment for baclofen overdose. Postgrad Med J 1981;57:580-1.  Back to cited text no. 11  [PUBMED]  [FULLTEXT]
12.Chen KS, Bullard MJ, Chien YY, Lee SY. Baclofen toxicity in patients with severely impaired renal function. Ann Pharmacother 1997;31:1315-20.  Back to cited text no. 12  [PUBMED]  

Copyright 2009 - Indian Journal of Pharmacology

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2024, Site last up-dated on 01-Sep-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Google Cloud Platform, GCP, Brazil